Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 1/20 | 0.58 |
| ▸ | FDPS | P14324 | 1/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720762 | 0.81 | ALDH1A1 (0.42) | GGPS1FDPSPIK3CAPKMFLT3 | |
| SCHEMBL12732656 | 0.81 | GGPS1 (0.60) | GGPS1FDPSGPR84NPSR1DRD4 | |
| SCHEMBL4716274 | 0.80 | GGPS1 (0.40) | GGPS1FDPSPKMMAPTCYP1A2 | |
| SCHEMBL4716769 | 0.78 | FEN1 (0.36) | GGPS1FDPS | |
| SCHEMBL4717663 | 0.77 | GGPS1 (0.37) | GGPS1FDPSSSTR4 | |
| SCHEMBL12806413 | 0.77 | GGPS1 (0.56) | GGPS1FDPSGPR84NPSR1DRD4 | |
| SCHEMBL4714601 | 0.76 | ALDH1A1 (0.40) | GGPS1FDPSPKMRAB9AMAPT | |
| SCHEMBL25245613 | 0.76 | GGPS1 (0.46) | GGPS1FDPSGPR84NPSR1PTGS1 | |
| SCHEMBL4718724 | 0.74 | ATP4A (0.46) | MAPTCYP1A2CYP2C9 | |
| Minodronic Acid SCHEMBL145238 | 0.73 | FDPS (1.00) | GGPS1FDPSGPR84NPSR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448561-B1 | BETA 3 ADRENERGIC AGONISTS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7265127-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-7253181-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-7241772-B2 | β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7205407-B2 | 3-Substituted oxindole β3 agonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7071208-B2 | β3 Adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060142328-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20060142327-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| US-20060142329-A1 | BETA 3 ADRENERGIC AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2006-06-29 | — | — | US | disclosed |
| EP-1448560-B1 | 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS | LILLY CO ELI (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20050020618-A1 | Beta 3 adrenergic agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2005-01-27 | — | — | US | disclosed |
| US-20050020617-A1 | 3-substituted oxindole beta3 agonists | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2005-01-27 | — | — | US | disclosed |
| EP-1448561-A1 | BETA 3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1448560-A1 | 3-SUBSTITUTED OXINDOLE $g(b)3 AGONISTS | ELI LILLY AND COMPANY (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003044016-A1 | 3-SUBSTITUTED OXINDOLE β3 AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003044017-A1 | BETA 3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-30 | — | — | WO | disclosed |
| US-5001132-A | Phenyloxypropanolamine derivatives and their application in therapeutics | SYNTHELABO (FR) | 1991-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142329-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | GGPS1 2897/4885FDPS 4473/4885GPR84 35/4885 |
| US-20050020618-A1 | Beta 3 adrenergic agonists | ADRB3, ADRB1, ADRB2 | GGPS1 2897/4885FDPS 4473/4885GPR84 35/4885 |
| US-20050020617-A1 | 3-substituted oxindole beta3 agonists | ADRB3, ADRB2, ADRA2C | GGPS1 3528/4885FDPS 4720/4885GPR84 116/4885 |
| US-20060142328-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | GGPS1 2897/4885FDPS 4473/4885GPR84 35/4885 |
| US-20060142327-A1 | BETA 3 ADRENERGIC AGONISTS | ADRB3, ADRB1, ADRB2 | GGPS1 2505/4885FDPS 4391/4885GPR84 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.